GlobeNewswire by notified

Evolution Credit Limited - Partial redemption of Nordic senior bonds and updated guidance regarding expected future bond repayments

Share

Evolution Credit Limited up to SEK 260,000,000 and up to NOK 135,000,000 Senior Unsecured Callable Bonds 2013/2028 ISIN: SE 000 5392560 and NO 001 0689342 (the "Bonds")

Johannesburg, 31 August 2022

Reference is made to the terms and conditions for the Bonds, originally dated 16 September 2013, as amended and restated, most recently by an amendment and restatement agreement dated 22 September 2020 (the "Terms and Conditions").

Partial repayment

In addition to scheduled amortizations, the Company is obliged to apply excess cash to repay Senior Unsecured Loans, If repayments are made under Senior Unsecured Loans, corresponding pro rata payments shall be made under the Bonds. The Company will therefore make an increased early partial redemption of the Bonds pursuant to Clauses 9.6 (Mandatory redemption pro rata in case of repayment of the Senior Unsecured Loan) and 11 (Cash Sweep) of the Terms and Conditions as further set out below.

Payment details

SEK Bonds (ISIN: SE 000 5392560)

The SEK Bonds will be partially redeemed on 30 September 2022 in a total amount of SEK 1,993,592.00. The record date, on which a bondholder must hold SEK Bonds in order to receive the redeemed amount, will be 22 September 2022.

The partial redemption of the SEK Bonds will be made as partial prepayments of all outstanding SEK Bonds by way of reducing the registered Nominal Amount of each SEK Bond with an amount of SEK  15,378.00. Due to the fact that the Nominal Amount registered with the CSD does not include capitalised interest, the repayment will appear to be made at a price of 102.07813% of the amount by which the registered Nominal Amount will be reduced as a result of the repayment. The amount is rounded down to the nearest SEK 1.00 per SEK Bond.

NOK Bonds (ISIN: NO 001 0689342)

The NOK Bonds will be partially redeemed on 30 September 2022 in a total amount of NOK 1,551,646.15. The record date, on which a bondholder must hold NOK Bonds in order to receive the redeemed amount, will be 27 September 2022.

The partial redemption of the NOK Bonds will be made by pro rata payments to the bondholders holding NOK Bonds through redeeming NOK Bonds with a total registered Nominal Amount of NOK  1,516,380.00. Due to the fact that the outstanding Nominal Amount registered with the CSD does not include capitalised interest, the repayment will appear to be made at a price of 102.32568% of the amount by which the registered Nominal Amount will be reduced as a result of the redemption. The amount is rounded down to effect a pro-rata repayment to the bondholders in accordance with the rules of the CSD.

Updated guidance regarding expected partial repayments under the Bonds

Clause 10 (Minimum repayment undertaking) of the Terms and Conditions prescribes that the Issuer must meet certain minimum amortization levels. In addition, pursuant to clause 9.3 (Mandatory redemption pro rata in case of repayment of the Senior Unsecured Loan) of the Terms and Conditions, the Issuer shall redeem the Bonds in an amount equal to the Bonds Pro-rata Share (as defined in the Terms and Conditions) if any repayment is made to the senior lenders under the senior unsecured loan agreement. The Issuer has agreed a new amortization profile with the senior lenders under the senior unsecured loan agreement as set out int the table below. The table has been updated to reflect the effects of cash sweep payments and replaces the guidance published on 2 June 2022 Corresponding Bonds Pro-rata Share payments will be made under the Bonds. It is expected that the amortizations that will be made with respect to the Bonds as a result of the above-mentioned provisions will meet the minimum repayment undertaking applicable for the Bonds.

Repayment DateRepayment Instalment as a percentage of
the total Outstandings as at 31 March 2018
30 September 20222.489610%
31 December 20220.2164200%
31 March 20231.0271400%
30 June 20231.5673300%
30 September 20230.3901500%
31 December 20230.5499800%
31 March 20241.6478100%
30 June 20241.9153000%
30 September 20240.8813900%
31 December 20240.5961800%
31 March 20251.7437800%
30 June 20251.8572000%
30 September 20250.7723400%
31 December 20250.5311280%
31 March 20261.9606002%

Due to slightly different bases used for the purpose of the calculations and currency conversion effects, the amortizations under the Bonds will not correspond exactly with the amortizations under the senior unsecured loan, but the figures can be used as a broad indication of the amortizations that can be expected under the Bonds. The Issuer will publish information on amounts to be repaid under the Bonds and repayment dates when they have been determined in connection with the repayments.

For further information, please contact:

Jacques Hefer, Head of Treasury

Email: jacques.hefer@evolution.za.com

Phone number: +27 84 514 3018

This information is information that Evolution Credit Limited is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10:00 am CET on 31 August 2022.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

GXO Reports First Quarter 2024 Results7.5.2024 22:30:00 CEST | Press release

First quarter revenue of $2.5 billion, up 6% year over year; organic revenue growth1 of 1%Signed new business wins of approximately $250 million in annualized revenue in 1Q 2024; up 55% year over yearSales pipeline at 12-month high of $2.2 billionCompleted acquisition of Wincanton on April 29, 2024 GREENWICH, Conn., May 07, 2024 (GLOBE NEWSWIRE) -- GXO Logistics, Inc. (NYSE: GXO) today announced results for the first quarter 2024. Malcolm Wilson, chief executive officer of GXO, said, “We delivered a strong start to 2024, reflecting our solid execution amid improving industry dynamics. The company grew revenue by 6% to $2.5 billion and delivered positive organic revenue growth, while gaining market share. We look forward to driving continued growth throughout 2024 and are on track to achieve our full-year outlook. “We’re seeing strengthening demand from global blue-chip customers to realize operational efficiencies today while planning fulfillment strategies to meet their future needs.

DBV Technologies Reports First Quarter 2024 Financial Results and Business Update7.5.2024 22:30:00 CEST | Press release

Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024Appointment of Robert Pietrusko, PharmD to Chief Regulatory OfficerQ1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the first quarter 2024. The quarterly financial statements were approved by the Board of Directors on May 7, 2024. Recent Business Developments Clinical and Regulatory Update Enrollment for VITESSE, DBV’s Phase 3 pivotal study of the modified Viaskin Peanut patch in children ages 4 through 7 years with peanut allergy passed the halfway point for recruitment in Q1 and continues to be on track to screen the last patient by

SFL - Invitation to Presentation of Q1 2024 Results7.5.2024 22:19:00 CEST | Press release

SFL Corporation Ltd. ("SFL" or the “Company”) (NYSE: SFL) plans to release its preliminary financial results for the first quarter of 2024 on Tuesday, May 14, 2024. SFL plans to host a conference call and webcast for all stakeholders and interested parties on Tuesday, May 14, 2024, at 10:00 AM (EST) / 4:00 PM (CET). Relevant material will on the same day be available from the Investor Relations section of the Company’s website at www.sflcorp.com. In order to listen to the conference call and presentation, you may do one of the following: A: Join Conference CallWebcast In Listen Only Mode: Visit the Investor Relations section of the Company’s website at www.sflcorp.com and click on the link to "Webcast", or access directly via the webcast link below. The webcast with slideshow will be played live from this platform: SFL Corporation Ltd. Q1 2024 Webcast B: Join Conference Call AndParticipate in Live Q&AthroughZoom: Join through the Zoom link below to ask a question: SFL Q1 2024 Q&A Meeti

Oculis Publishes Invitation to the Annual General Meeting7.5.2024 22:05:00 CEST | Press release

Zug, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), has published the invitation to the 2024 Annual General Meeting, which will be held on 29 May 2024 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:30 p.m. CEST / 9:30 a.m. EDT. All information pertaining to the 2024 Annual General Meeting, including meeting materials, can be accessed on the Oculis website at https://investors.oculis.com/events-presentations. About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior

Nokia Corporation: Repurchase of own shares on 07.05.20247.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 07 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 07.05.2024 Espoo, Finland – On 07 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL376,2023.48CEUX--BATE--AQEU--TQEX--Total376,2023.48 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

HiddenA line styled icon from Orion Icon Library.Eye